Hence, in contrast to intense, early onset insulin therapy, inceptor-mediated improvement of β cell function may offer the potential to counteract the detrimental glucometabolic effects of DIO without the risk of causing hypoglycaemia or unwanted body weight gain. Here, INS is linked to Hypoglycemia.